Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on October 9, 2012, at a price of 1447.91 pence per share through the Company's ShareReward Plan. Transactions included both personal contributions and matching company contributions:
- Sir Andrew Witty: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S Dingemans: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S M Bicknell: Acquired 9 shares (personal) and 9 shares (company match).
- Mr R G Connor: Acquired 9 shares (personal) and 9 shares (company match).
- Mr D S Redfern: Acquired 9 shares (personal) and 9 shares (company match).
- Ms C Thomas: Acquired 9 shares (personal) and 9 shares (company match).
- Mr P C Thomson: Acquired 7 shares (personal) and 7 shares (company match).
- Dr P J T Vallance: Acquired 8 shares (personal) and 8 shares (company match).
- Ms E Walmsley: Acquired 9 shares (personal) and 9 shares (company match).
- Mrs V A Whyte: Acquired 9 shares (personal) and 9 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share ownership changes in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares acquired by each named executive under the ShareReward Plan.
- Confirm the transaction price of 1447.91 pence per share against market data for October 9, 2012.
- Review the company's broader annual or quarterly reports for financial performance metrics not included in this specific 6-K filing.